Chardan Capital Maintains Buy on MeiraGTx Hldgs, Lowers Price Target to $35

Written by Emily J. Thompson, Senior Investment Analyst

Source: Benzinga

Updated: May 14 2025

0mins

MGTX+3.19%

Should l Buy MGTX?

Source: Benzinga

Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and exclusive stories to help traders make informed decisions in the stock market.
Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from accurate market intelligence and insights.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy MGTX?" and start using high-conviction signals backed by rigorous historical data.

MGTX

$7.43+Infinity%1D

Analyst Views on MGTX

Wall Street analysts forecast MGTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MGTX is 21.50 USD with a low forecast of 14.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Analyst Rating

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 7.200

Low

14.00

Averages

21.50

High

30.00

Current: 7.200

Low

14.00

Averages

21.50

High

30.00

BofA

Buy

downgrade

$15 -> $14

2026-01-06

Reason

BofA

Price Target

$15 -> $14

AI Analysis

2026-01-06

downgrade

Buy

Reason

BofA lowered the firm's price target on MeiraGTx to $14 from $15 and keeps a Buy rating on the shares. The firm is updating its price targets for U.S Biopharmaceuticals under its coverage, the analyst tells investors. Over the past few months, several key items "have fallen into place," including positive data catalysts being rewarded; large-cap biopharma spending cash on M&A and in-licensing; growing backlog of companies on the private side; improving access to capital; and limited impact from drug price regulation, BofA says. The firm believes biotech is back, but the biggest concern is whether this will last.

H.C. Wainwright

Mitchell Kapoor

Buy

initiated

$20

2025-11-24

Reason

H.C. Wainwright

Mitchell Kapoor

Price Target

$20

2025-11-24

initiated

Buy

Reason

H.C. Wainwright analyst Mitchell Kapoor initiated coverage of MeiraGTx with a Buy rating and $20 price target. The firm has conviction that AAV-AQP1 for radiation-induced xerostomia is one of the most "risk-mitigated late-stage gene therapy programs in development." It recommends buying the shares ahead of the pivotal data in late 2026 or early 2027.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MGTX

Unlock Now

About MGTX

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company. It has a pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It is focused on vivo delivery of vectorized biologic therapeutics addressing unmet needs in prevalent disorders, including severe forms of xerostomia, neurodegenerative diseases and ocular diseases, including inherited retinal diseases (IRDs), and large degenerative ocular diseases. The Company’s product pipeline includes Botaretigene Sparoparvovec for the treatment of X-linked Retinitis Pigmentosa; AAV-hAQP1 for the treatment of Radiation-Induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of LCA4, and others.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Eli Lilly Enhances Genetic Eye Disease Pipeline Through Collaboration with MeiraGTx on Gene Therapy

Nov 10 2025Benzinga

MeiraGTx and Eli Lilly Collaboration: MeiraGTx Holdings has entered a strategic partnership with Eli Lilly, granting exclusive rights to its AAV-AIPL1 program for treating Leber congenital amaurosis 4, with an upfront payment of $75 million and potential milestone payments exceeding $400 million.
Clinical Success of AAV-AIPL1: Clinical trials showed that all 11 children treated with AAV-AIPL1 gained vision, with additional improvements in communication, behavior, learning, and social integration.
Riboswitch Technology: The collaboration includes access to MeiraGTx’s riboswitch technology for gene editing in ophthalmology, allowing precise control over therapeutic protein production through oral dosing.
SanegeneBio and Eli Lilly Partnership: SanegeneBio has also partnered with Eli Lilly to advance RNAi candidates for metabolic diseases, with potential milestone payments up to $1.2 billion and a focus on developing therapies that can be administered infrequently.

Eli Lilly Partners with MeiraGTx to Create Gene Therapies for Ocular Disorders

Nov 10 2025SeekingAlpha

Collaboration Announcement: MeiraGTx (MGTX) shares rose approximately 18% in premarket trading after announcing a strategic collaboration with Eli Lilly (LLY) to develop gene therapies for eye diseases, specifically targeting Leber congenital amaurosis 4 (LCA4).
Exclusive Rights and Financial Terms: Under the agreement, Eli Lilly will receive exclusive global rights to MGTX's AAV-AIPL1 gene therapy program and other gene therapy technologies, with MeiraGTx set to receive $75 million upfront and over $400 million based on milestone achievements, along with tiered royalties on future sales.

Raymond James Begins Coverage of MeiraGTx Holdings with Strong Buy Rating and Sets Price Target at $29

Oct 21 2025Benzinga

Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, indicating a robust network for sharing market intelligence.
Market Winning Tools: Benzinga Pro is designed to equip traders with the tools and information necessary to succeed in the markets daily.

Insider Sale: CFO & COO of $MGTX Sells 24,000 Shares

Jul 23 2025NASDAQ.COM

Insider Trading Activity: Richard Giroux, CFO & COO of $MGTX, sold 24,000 shares for approximately $204,480, marking a 2.7% reduction in his holdings, with no insider purchases reported in the last six months.
Analyst Ratings and Institutional Activity: Recent reports show that 59 institutional investors increased their stakes in $MGTX, while analysts have issued two buy ratings and set a median price target of $24.0 for the stock.

Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday

May 14 2025Benzinga

Analyst Rating Changes: Various Wall Street analysts have adjusted their price targets for several companies, with notable changes including HC Wainwright lowering Annexon, Inc.'s target from $20 to $14 while maintaining a Buy rating, and Rosenblatt increasing Coinbase Global, Inc.'s target from $260 to $300, also keeping a Buy rating.
Stock Performance Insights: Other companies such as V.F. Corporation and Camtek Ltd saw their price targets cut, while Wingstop Inc. and Danaos Corporation had their targets raised, reflecting mixed sentiments in the market regarding these stocks.